OX40(CD134) expression on CAR T cell surface improves anti-tumor activity in a mouse model. “OX40–heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice” Huihui Zhang, Xuanming Yang, et al. (18 June 2025) Science Translational Medicine 17(803):eadr2151. doi: 10.1126/scitranslmed.adr2151. Epub 2025 Jun 18. PMID: 405 Related Ancell Products anti-human CD134(OX40) mAb anti-human […]

Authors review utilization of various types of humanized mice to study human immunological mechanisms. Challenges include engineering humanized populations of Neutrophils, Red Blood Cells, Hepatocytes, and resident Skin macrophages. They cite and recommend multi-omic canonical correlations of human vs humanized mouse biomarkers to assess the utility of these technologies. “Engineering Mice to Study Human Immunity”

Hyper IgM Syndrome is an immune disorder usuallycaused by an X-linked mutation in the CD40L(CD154) gene. In this study,the authors were able to discern an altered CD40L phenotypein a patient. While anti-CD40L mAbs still recognized the molecule in flow cytometry, a recombinant CD40 reagent failed to bind. Genetic analysis determined this to be caused by

IgA Nephropathy is one of the leading causes of kidney failure worldwide. It is caused by production of IgA1 antibodies lacking galactose in their o-Glycan regions, which cause them to be auto antigenic and can lead to protein aggregates. Traditional treatments have been limited to kidney care lifestyle modification and high-dose long term glucocordicosteroids. More

“Can autoimmune disease be cured by deep CD19+ cell depletion?” Dan Suan, John Moore, Christopher C Goodnow. J Immunol. 2025 Jun 1;214(6):1075-1092. doi: 10.1093/jimmun/vkaf008. PMID: 40116909 The Authors review encouraging data from B cell autoimmune patients in relapse after CD20 treatments who were given CD19 CAR T cell treatment, or blinumomab anti-CD19 bispecific T cell

Autolus Therapeutics tested the toxicity and efficacy of AUTO4, a TRBC1 specific CAR cell therapeutic on 10 relapsed/refractory T cell lymphoma patients. This treatment appears to be safe with only minimal toxicity. The CAR T cells were shown to be residing in the majority of patient lymph nodes.Ancell anti-TRBC1/Biotin (clone Jovi-1) was used to sort

Recipients who received 2nd Covid booster with a longer than recommended interval from 1st immunization had improved specific antibody response, but asimilar T cell response. This differential effect was nullified by a 3rdbooster. “Improved antibody breadth with an extended primary dose interval of COVID-19 vaccine is overcome by boosters” JI Ahmed, CM Card, et al.

“Is one lymphocyte’s brake another lymphocyte’s gas?” Thomas T Xu, Shiv Pillai. (Feb 7, 2025) Sci Immunol 10(104): eadw3656 doi: 10.1126/sciimmunol.adw365 PMID: 39919195 PD-1 (CD279) binding to its ligand PD-L1 (CD274) is down regulatory for T cell immune response in the context of cancer. However, studies are showing that this interaction is required for development

Cyclophilin A is a ligand for RAGE in thrombo-inflammation Peter Seizer, David Heinzmann, et al. (March 2024) Cardiovascular Research 120(4): 385–402, https://doi.org/10.1093/cvr/cvad189 Ancell anti-human CD147 mAb was used for detection and to block activation of cells by Cyclophilan A Related Ancell Products anti-human CD147( EMMPRIN) mAb

“Non Classical” (CCR2+ CD16++ CD14+ MHC Class II+ CD209+) subset of mouse monocytes were expanded using NOD2 small-molecule activators. CCR2 enabled these cells to infiltrate tumors and inhibit metastasis in mouse models of colon, lung, breast and melanoma through CCL6 recruitment of NK cells. The monocyte CCR2/CCL2 axis merits further investigation for cancer intervention! “Inducible